test group:Candonilimab

3 trials

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, West China Hospital, Sichuan University, The First Affiliated Hospital of Zhengzhou University

Conditions

Biliary system tumorshepatocarcinoma

Early Phase 1

An exploratory study of Candonilimab (AK104) in combination with lenvatinib and stereotactic body radiotherapy for the conversion therapy of potentially resectable hepatocellular

Active, not recruitingChiCTR2300068781

Union Hospital, Tongji Medical College, Huazhong University of Science and Technologyhepatocarcinoma

Start: 2023-03-01Updated: 2023-05-22

Phase 2

Efficacy and safety of Cadonilimab combined with gemcitabine and cisplatin in the first-line treatment of unresectable locally advanced or metastatic biliary malignancies

Active, not recruitingChiCTR2300073023

West China Hospital, Sichuan UniversityBiliary system tumors

Start: 2023-06-30Updated: 2023-07-02

An exploratory study of Cadonilimab in combination with gemcitabine and S-1 in the first-line treatment of unresectable locally advanced or metastatic biliary tract tumors

RecruitingChiCTR2400085490

The First Affiliated Hospital of Zhengzhou UniversityBiliary system tumors

Start: 2024-06-15Updated: 2024-07-08

Related Papers

Stereotactic body radiotherapy plus cadonilimab and lenvatinib as conversion therapy for potentially resectable hepatocellular carcinoma (UniRTX): A phase II study.

Journal of Clinical Oncology2026-05-28

Cadonilimab Plus Lenvatinib Combined with Stereotactic Body Radiotherapy for Conversion Therapy in Unresectable or Potentially Resectable Hepatocellular Carcinoma: A Study Protocol.

2026-04-09

Abstract CT171: Cadonilimab in combination with lenvatinib and stereotactic body radiotherapy in potentially resectable hepatocellular carcinoma (UniRTX): A single-arm, phase II clinical trial

Cancer Research2025-04-25